So far, both RNA-seq and phenotypic assays on multiple cell lines suggest that the Gα13-MYC signaling mechanism is specific to ER+ breast cancer cells, which raises the possibility of the involvement of estrogen and/or estrogen receptor-dependent regulation in this novel Gα13-MYC signaling axis. This evidence concerns the gene ESR1 and breast carcinoma.